Description: Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
Home Page: www.ocumension.com
No. 1858 Yinzhongnan Road
Suzhou,
China
Phone:
86 21 6149 3800
Officers
| Name | Title |
|---|---|
| Mr. Ye Liu | CEO & Exec. Director |
| Dr. Changdong Liu | Chief Scientific Officer |
| Dr. Zhaopeng Hu | Chief Devel. Officer & Exec. Director |
| Dr. DongHong Chen | Chief Medical Officer |
| Mr. Qinglei Zuo | Chief Commercial Officer |
| Ms. Yun Ji | Joint Company Sec. |
| Ms. Hing Ling Chau FCIS, FCS, LLM | Joint Company Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8864 |
| Price-to-Sales TTM: | 67.0001 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 309 |